Results 71 to 80 of about 35,561 (168)

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. [PDF]

, 2015
Work in the Green lab is supported by Leukemia and Lymphoma Research, Cancer Research UK, the NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre, and the Leukemia and Lymphoma Society of America.
A Tefferi, A Tefferi, Claire N. Harrison, E Puigdecanet, F Passamonti, H Yoshida, J Nangalia, John T. Reilly, M Michalak, M Wictome, P Guglielmelli, R Rampal, S Schwemmers, S Verstovsek, S Verstovsek, T Klampfl   +15 more
core   +1 more source

Is Myeloproliferative Neoplasm with Splanchnic Vein Thrombosis a Distinct Clinical Entity? [PDF]

, 2015
Clinical History: A 29 year-old previously healthy female presented with sub-acute symptoms of weight loss, right upper quadrant pain and nausea. CBC results: WBC-11.7, Hb- 12.5, Platelet- 286, MCV- 90, MCV- 26.8, RDW- 18%.
Gong, MD, Jerald Z., Joneja, MD, Upasana, Uppal, MD, Guldeep   +2 more
core   +1 more source

Thrombotic and hemorrhagic complications in idiopathic erythrocytosis [PDF]

, 2017
We report clinical features of a large cohort of patients with IE compared to a cohort of patients with PV, focusing on the thrombotic and hemorrhagic ...
Bertozzi, Irene, Biagetti, Giacomo, Cosi, Elisabetta, Nichele, Ilaria, Randi, Maria Luigia, Ruggeri, Marco   +5 more
core   +1 more source

P212 | COMPARATIVE ANALYSIS OF MUTATION LANDSCAPE IN MPN PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS AND OTHER VEIN THROMBOSES

Haematologica
Introduction: Myeloproliferative neoplasms (MPNs) are a main cause of splanchnic vein thrombosis (SVT), with JAK2V617F as a known risk factor. The impact of co-occurring mutations on thrombosis risk remains unclear.
L. Fagiolo, V. Boldrini, G. Gaetano Loscocco, G. Coltro, G. Capecchi, G. Borgi, J. Caroprese, C. Matteoli, E. Nacca, G. Rotunno, C. Ghetti, A.M. Vannucchi, P. Guglielmelli   +12 more
doaj  

Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms

Haematologica, 2017
The myeloproliferative neoplasms are a heterogeneous group of clonal disorders characterized by the overproduction of mature cells in the peripheral blood, together with an increased risk of thrombosis and progression to acute myeloid leukemia.
Jacob Grinfeld, Jyoti Nangalia, Anthony R. Green   +2 more
doaj   +1 more source

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6 [PDF]

, 2017
Primary myelofibrosis (PMF) is a chronic Philadelphia-negative myeloproliferative neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation, involving especially the megakaryocyte lineage.
Barosi, Giovanni, Bianchi, Elisa, Guglielmelli, Paola, Manfredini, Rossella, Norfo, Ruggiero, Pennucci, Valentina, Prudente, Zelia, Rontauroli, Sebastiano, Rossi, Chiara, Rosti, Vittorio, Ruberti, Samantha, Salati, Simona, Tagliafico, Enrico, Vannucchi, Alessandro, Zini, Roberta   +14 more
core   +1 more source

Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. [PDF]

, 2017
Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record number of 42 171 HSCT in 37 626 patients (16 030 allogeneic (43%), 21 596 autologous (57%)) were ...
A Gennery, A Gratwohl, A Gratwohl, A Gratwohl, A Gratwohl, A Gratwohl, A Gratwohl, A Gratwohl, A Nagler, C Bonini, C Bonini, C Dufour, CG Brunstein, D Jeyakumar, EA Copelan, F Lanza, FR Appelbaum, H Baldomero, J A Snowden, J Kuball, J R Passweg, J Styczynski, J Tolar, JR Passweg, JR Passweg, JR Passweg, JR Passweg, L Luznik, LM Foeken, M Mohty, N Kröger, P Bader, P Ljungman, R F Duarte, S Montoto   +34 more
core   +3 more sources

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Haematologica, 2017
The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life.
Holly L. Geyer, Heidi Kosiorek, Amylou C. Dueck, Robyn Scherber, Stefanie Slot, Sonja Zweegman, Peter AW te Boekhorst, Zhenya Senyak, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Döhner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Chiara Paoli, Francesco Passamonti, Bjorn Andreasson, Maria L Ferrari, Alessandro Rambaldi, Jan Samuelsson, Keith Cannon, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Jean-Jacques Kiladjian, Peihong Zhang, Robert Peter Gale, Ruben A. Mesa   +51 more
doaj   +1 more source

Hematopoietic-restricted Ptpn11E76K reveals indolent MPN progression in mice [PDF]

, 2018
Juvenile Myelomonocytic Leukemia (JMML) is a pediatric myeloproliferative neoplasm (MPN) that has a poor prognosis. Somatic mutations in Ptpn11 are the most frequent cause of JMML and they commonly occur in utero.
Chan, Rebecca J., Qu, Cheng-Kui, Tarnawsky, Stefan P., Yoder, Mervin C., Yu, Wen-Mei   +4 more
core   +1 more source

Editorial: Membrane Processes in Erythroid Development and Red Cell Life Time

Frontiers in Physiology, 2021
Giampaolo Minetti, Anna Rita Migliaccio, Anna Rita Migliaccio, Eitan Fibach   +3 more
doaj   +1 more source